Search

Introduction: Several psychiatric disorders and medications used to treat them appear to be independently associated with skeletal deficits. As there is increasing evidence that lithium possesses skeletal protective properties, we aimed to investigate the association between lithium use and bone health in a group of women with bipolar disorder. Method: Women with bipolar disorder (n = 117, 20+ years) were recruited from south‐eastern Australia. Bipolar disorder was confirmed using a clinical interview (SCID‐I/NP). Bone mineral density (BMD; g/cm2) was measured at the spine, hip and total body using dual‐energy x‐ray absorptiometry and low bone mass determined by BMD T‐score of <−1.0. Weight and height were measured, socioeconomic status (SES) determined and information on medication use and lifestyle factors self‐reported. Linear and logistic regression were used to test associations between lithium and (i) BMD and (ii) low bone mass, respectively. Results: Thirty‐five (29.9%) women reported current lithium use. Lithium users and non‐users differed in regard to SES and BMD; otherwise, groups were similar. After adjustments, mean BMD among lithium users was 5.1% greater at the spine (1.275 [95% CI 1.229–1.321] vs. 1.214 [1.183–1.244] g/cm2, p = 0.03), 4.2% greater at the total hip (0.979 [0.942–1.016] vs. 0.938 [0.910–0.966] g/cm2, p = 0.03) and 2.2% greater at the total body (1.176 [1.148–1.205] vs. 1.150 [1.129–1.171] g/cm2, p = 0.08) compared to participants not receiving lithium. Lithium users were also less likely to have low bone mass (22.9% vs. 43.9%, p = 0.031). Associations persisted after adjustment for confounders. Conclusion: These data suggest lithium is associated with greater BMD and reduced risk of low bone mass in women with bipolar disorder. Research into the underlying mechanisms is warranted. [ABSTRACT FROM AUTHOR]

Objective: We aimed to describe the prevalence and age distribution of personality disorders and their comorbidity with other psychiatric disorders in an age-stratified sample of Australian women aged ⩾25 years. Methods: Individual personality disorders (paranoid, schizoid, schizotypal, histrionic, narcissistic, borderline, antisocial, avoidant, dependent, obsessive-compulsive), lifetime mood, anxiety, eating and substance misuse disorders were diagnosed utilising validated semi-structured clinical interviews (Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Non-patient Edition and Structured Clinical Interview for DSM-IV Axis II Personality Disorders). The prevalence of personality disorders and Clusters were determined from the study population (n = 768), and standardised to the Australian population using the 2011 Australian Bureau of Statistics census data. Prevalence by age and the association with mood, anxiety, eating and substance misuse disorders was also examined. Results: The overall prevalence of personality disorders in women was 21.8% (95% confidence interval [CI]: 18.7, 24.9). Cluster C personality disorders (17.5%, 95% CI: 16.0, 18.9) were more common than Cluster A (5.3%, 95% CI: 3.5, 7.0) and Cluster B personality disorders (3.2%, 95% CI: 1.8, 4.6). Of the individual personality disorders, obsessive-compulsive (10.3%, 95% CI: 8.0, 12.6), avoidant (9.3%, 95% CI: 7.1, 11.5), paranoid (3.9%, 95% CI: 3.1, 4.7) and borderline (2.7%, 95% CI: 1.4, 4.0) were among the most prevalent. The prevalence of other personality disorders was low (⩽1.7%). Being younger (25–34 years) was predictive of having any personality disorder (odds ratio: 2.36, 95% CI: 1.18, 4.74), as was being middle-aged (odds ratio: 2.41, 95% CI: 1.23, 4.72). Among the strongest predictors of having any personality disorder was having a lifetime history of psychiatric disorders (odds ratio: 4.29, 95% CI: 2.90, 6.33). Mood and anxiety disorders were the most common comorbid lifetime psychiatric disorders. Conclusions: Approximately one in five women was identified with a personality disorder, emphasising that personality disorders are relatively common in the population. A more thorough understanding of the distribution of personality disorders and psychiatric comorbidity in the general population is crucial to assist allocation of health care resources to individuals living with these disorders. [ABSTRACT FROM AUTHOR]

The article presents a study on the association between use of antidepressants, mainly selective serotonin reuptake inhibitors (SSRI), and bone quality, as measured by heel quantitative ultrasound (QUS). Topics include data from the Geelong Osteoporosis Study in south-eastern Australia, the lower mean broadband ultrasound attenuation (BUA) found in antidepressant users, and how the risk of osteoporosis is only higher in antidepressant users with low body weights.